 | • レポートコード：MRC2-11QY08112 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、150ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は神経内分泌腫瘍治療薬のグローバル市場について調査・分析したレポートです。種類別（神経内分泌腫瘍薬mTORタンパク質阻害剤、チロシンキナーゼ3阻害剤、ソマトスタチン受容体拮抗薬、成長ホルモン放出因子拮抗薬、ソマトスタチン受容体作動薬、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別神経内分泌腫瘍治療薬の競争状況、市場シェア ・世界の神経内分泌腫瘍治療薬市場：種類別市場規模 2015年-2020年（神経内分泌腫瘍薬mTORタンパク質阻害剤、チロシンキナーゼ3阻害剤、ソマトスタチン受容体拮抗薬、成長ホルモン放出因子拮抗薬、ソマトスタチン受容体作動薬、その他） ・世界の神経内分泌腫瘍治療薬市場：種類別市場規模予測 2021年-2026年（神経内分泌腫瘍薬mTORタンパク質阻害剤、チロシンキナーゼ3阻害剤、ソマトスタチン受容体拮抗薬、成長ホルモン放出因子拮抗薬、ソマトスタチン受容体作動薬、その他） ・世界の神経内分泌腫瘍治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の神経内分泌腫瘍治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の神経内分泌腫瘍治療薬市場分析：米国、カナダ ・ヨーロッパの神経内分泌腫瘍治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの神経内分泌腫瘍治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の神経内分泌腫瘍治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの神経内分泌腫瘍治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Eisai、Exelixis, Inc.、Foresee Pharmaceuticals, LLC、Hutchison MediPharma Limited、Intezyne, Inc、INVENT Pharmaceuticals, Inc.、Ipsen S.A.、Jiangsu Hengrui Medicine Co., Ltd.、Karyopharm Therapeutics, Inc.、Lexicon Pharmaceuticals, Inc.、Midatech Pharma Plc .、Millennium Pharmaceuticals, Inc.、MolMed S.p.A.、Northwest Biotherapeutics, Inc.、Novartis AG、OctreoPharm Sciences GmbH、OXiGENE, Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Neuroendocrine Tumor Drug Market
The global Neuroendocrine Tumor Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Neuroendocrine Tumor Drug Scope and Market Size
Neuroendocrine Tumor Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neuroendocrine Tumor Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Neuroendocrine Tumor Drug market is segmented into
mTOR protein inhibitors
Tyrosine kinase 3 inhibitors
Somatostatin receptor antagonists
Growth hormone releasing factor antagonists
Somatostatin receptor agonists
Others
Segment by Application, the Neuroendocrine Tumor Drug market is segmented into
Hospital
Clinic
Others
Regional and Country-level Analysis
The Neuroendocrine Tumor Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neuroendocrine Tumor Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Neuroendocrine Tumor Drug Market Share Analysis
Neuroendocrine Tumor Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neuroendocrine Tumor Drug business, the date to enter into the Neuroendocrine Tumor Drug market, Neuroendocrine Tumor Drug product introduction, recent developments, etc.
The major vendors covered:
Eisai
Exelixis, Inc.
Foresee Pharmaceuticals, LLC
Hutchison MediPharma Limited
Intezyne, Inc
INVENT Pharmaceuticals, Inc.
Ipsen S.A.
Jiangsu Hengrui Medicine Co., Ltd.
Karyopharm Therapeutics, Inc.
Lexicon Pharmaceuticals, Inc.
Midatech Pharma Plc .
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Northwest Biotherapeutics, Inc.
Novartis AG
OctreoPharm Sciences GmbH
OXiGENE, Inc.
1 Study Coverage
1.1 Neuroendocrine Tumor Drug Product Introduction
1.2 Market Segments
1.3 Key Neuroendocrine Tumor Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Type
1.4.2 mTOR protein inhibitors
1.4.3 Tyrosine kinase 3 inhibitors
1.4.4 Somatostatin receptor antagonists
1.4.5 Growth hormone releasing factor antagonists
1.4.6 Somatostatin receptor agonists
1.4.7 Others
1.5 Market by Application
1.5.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Neuroendocrine Tumor Drug Market Size, Estimates and Forecasts
2.1.1 Global Neuroendocrine Tumor Drug Revenue 2015-2026
2.1.2 Global Neuroendocrine Tumor Drug Sales 2015-2026
2.2 Global Neuroendocrine Tumor Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Neuroendocrine Tumor Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Neuroendocrine Tumor Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Neuroendocrine Tumor Drug Competitor Landscape by Players
3.1 Neuroendocrine Tumor Drug Sales by Manufacturers
3.1.1 Neuroendocrine Tumor Drug Sales by Manufacturers (2015-2020)
3.1.2 Neuroendocrine Tumor Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Neuroendocrine Tumor Drug Revenue by Manufacturers
3.2.1 Neuroendocrine Tumor Drug Revenue by Manufacturers (2015-2020)
3.2.2 Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neuroendocrine Tumor Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neuroendocrine Tumor Drug Revenue in 2019
3.2.5 Global Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Neuroendocrine Tumor Drug Price by Manufacturers
3.4 Neuroendocrine Tumor Drug Manufacturing Base Distribution, Product Types
3.4.1 Neuroendocrine Tumor Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neuroendocrine Tumor Drug Product Type
3.4.3 Date of International Manufacturers Enter into Neuroendocrine Tumor Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Neuroendocrine Tumor Drug Market Size by Type (2015-2020)
4.1.1 Global Neuroendocrine Tumor Drug Sales by Type (2015-2020)
4.1.2 Global Neuroendocrine Tumor Drug Revenue by Type (2015-2020)
4.1.3 Neuroendocrine Tumor Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neuroendocrine Tumor Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Neuroendocrine Tumor Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Type (2021-2026)
4.2.3 Neuroendocrine Tumor Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neuroendocrine Tumor Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Neuroendocrine Tumor Drug Market Size by Application (2015-2020)
5.1.1 Global Neuroendocrine Tumor Drug Sales by Application (2015-2020)
5.1.2 Global Neuroendocrine Tumor Drug Revenue by Application (2015-2020)
5.1.3 Neuroendocrine Tumor Drug Price by Application (2015-2020)
5.2 Neuroendocrine Tumor Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Neuroendocrine Tumor Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Neuroendocrine Tumor Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Neuroendocrine Tumor Drug by Country
6.1.1 North America Neuroendocrine Tumor Drug Sales by Country
6.1.2 North America Neuroendocrine Tumor Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Neuroendocrine Tumor Drug Market Facts & Figures by Type
6.3 North America Neuroendocrine Tumor Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Neuroendocrine Tumor Drug by Country
7.1.1 Europe Neuroendocrine Tumor Drug Sales by Country
7.1.2 Europe Neuroendocrine Tumor Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neuroendocrine Tumor Drug Market Facts & Figures by Type
7.3 Europe Neuroendocrine Tumor Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Neuroendocrine Tumor Drug by Region
8.1.1 Asia Pacific Neuroendocrine Tumor Drug Sales by Region
8.1.2 Asia Pacific Neuroendocrine Tumor Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Neuroendocrine Tumor Drug Market Facts & Figures by Type
8.3 Asia Pacific Neuroendocrine Tumor Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Neuroendocrine Tumor Drug by Country
9.1.1 Latin America Neuroendocrine Tumor Drug Sales by Country
9.1.2 Latin America Neuroendocrine Tumor Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Neuroendocrine Tumor Drug Market Facts & Figures by Type
9.3 Central & South America Neuroendocrine Tumor Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Neuroendocrine Tumor Drug by Country
10.1.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country
10.1.2 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Neuroendocrine Tumor Drug Market Facts & Figures by Type
10.3 Middle East and Africa Neuroendocrine Tumor Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Eisai
11.1.1 Eisai Corporation Information
11.1.2 Eisai Description and Business Overview
11.1.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Eisai Neuroendocrine Tumor Drug Products Offered
11.1.5 Eisai Related Developments
11.2 Exelixis, Inc.
11.2.1 Exelixis, Inc. Corporation Information
11.2.2 Exelixis, Inc. Description and Business Overview
11.2.3 Exelixis, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Exelixis, Inc. Neuroendocrine Tumor Drug Products Offered
11.2.5 Exelixis, Inc. Related Developments
11.3 Foresee Pharmaceuticals, LLC
11.3.1 Foresee Pharmaceuticals, LLC Corporation Information
11.3.2 Foresee Pharmaceuticals, LLC Description and Business Overview
11.3.3 Foresee Pharmaceuticals, LLC Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Products Offered
11.3.5 Foresee Pharmaceuticals, LLC Related Developments
11.4 Hutchison MediPharma Limited
11.4.1 Hutchison MediPharma Limited Corporation Information
11.4.2 Hutchison MediPharma Limited Description and Business Overview
11.4.3 Hutchison MediPharma Limited Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Products Offered
11.4.5 Hutchison MediPharma Limited Related Developments
11.5 Intezyne, Inc
11.5.1 Intezyne, Inc Corporation Information
11.5.2 Intezyne, Inc Description and Business Overview
11.5.3 Intezyne, Inc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Intezyne, Inc Neuroendocrine Tumor Drug Products Offered
11.5.5 Intezyne, Inc Related Developments
11.6 INVENT Pharmaceuticals, Inc.
11.6.1 INVENT Pharmaceuticals, Inc. Corporation Information
11.6.2 INVENT Pharmaceuticals, Inc. Description and Business Overview
11.6.3 INVENT Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
11.6.5 INVENT Pharmaceuticals, Inc. Related Developments
11.7 Ipsen S.A.
11.7.1 Ipsen S.A. Corporation Information
11.7.2 Ipsen S.A. Description and Business Overview
11.7.3 Ipsen S.A. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Ipsen S.A. Neuroendocrine Tumor Drug Products Offered
11.7.5 Ipsen S.A. Related Developments
11.8 Jiangsu Hengrui Medicine Co., Ltd.
11.8.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
11.8.2 Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
11.8.3 Jiangsu Hengrui Medicine Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Products Offered
11.8.5 Jiangsu Hengrui Medicine Co., Ltd. Related Developments
11.9 Karyopharm Therapeutics, Inc.
11.9.1 Karyopharm Therapeutics, Inc. Corporation Information
11.9.2 Karyopharm Therapeutics, Inc. Description and Business Overview
11.9.3 Karyopharm Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Products Offered
11.9.5 Karyopharm Therapeutics, Inc. Related Developments
11.10 Lexicon Pharmaceuticals, Inc.
11.10.1 Lexicon Pharmaceuticals, Inc. Corporation Information
11.10.2 Lexicon Pharmaceuticals, Inc. Description and Business Overview
11.10.3 Lexicon Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
11.10.5 Lexicon Pharmaceuticals, Inc. Related Developments
11.1 Eisai
11.1.1 Eisai Corporation Information
11.1.2 Eisai Description and Business Overview
11.1.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Eisai Neuroendocrine Tumor Drug Products Offered
11.1.5 Eisai Related Developments
11.12 Millennium Pharmaceuticals, Inc.
11.12.1 Millennium Pharmaceuticals, Inc. Corporation Information
11.12.2 Millennium Pharmaceuticals, Inc. Description and Business Overview
11.12.3 Millennium Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Millennium Pharmaceuticals, Inc. Products Offered
11.12.5 Millennium Pharmaceuticals, Inc. Related Developments
11.13 MolMed S.p.A.
11.13.1 MolMed S.p.A. Corporation Information
11.13.2 MolMed S.p.A. Description and Business Overview
11.13.3 MolMed S.p.A. Sales, Revenue and Gross Margin (2015-2020)
11.13.4 MolMed S.p.A. Products Offered
11.13.5 MolMed S.p.A. Related Developments
11.14 Northwest Biotherapeutics, Inc.
11.14.1 Northwest Biotherapeutics, Inc. Corporation Information
11.14.2 Northwest Biotherapeutics, Inc. Description and Business Overview
11.14.3 Northwest Biotherapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Northwest Biotherapeutics, Inc. Products Offered
11.14.5 Northwest Biotherapeutics, Inc. Related Developments
11.15 Novartis AG
11.15.1 Novartis AG Corporation Information
11.15.2 Novartis AG Description and Business Overview
11.15.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Novartis AG Products Offered
11.15.5 Novartis AG Related Developments
11.16 OctreoPharm Sciences GmbH
11.16.1 OctreoPharm Sciences GmbH Corporation Information
11.16.2 OctreoPharm Sciences GmbH Description and Business Overview
11.16.3 OctreoPharm Sciences GmbH Sales, Revenue and Gross Margin (2015-2020)
11.16.4 OctreoPharm Sciences GmbH Products Offered
11.16.5 OctreoPharm Sciences GmbH Related Developments
11.17 OXiGENE, Inc.
11.17.1 OXiGENE, Inc. Corporation Information
11.17.2 OXiGENE, Inc. Description and Business Overview
11.17.3 OXiGENE, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.17.4 OXiGENE, Inc. Products Offered
11.17.5 OXiGENE, Inc. Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Neuroendocrine Tumor Drug Market Estimates and Projections by Region
12.1.1 Global Neuroendocrine Tumor Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Regions 2021-2026
12.2 North America Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
12.2.1 North America: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
12.2.2 North America: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
12.2.3 North America: Neuroendocrine Tumor Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
12.3.2 Europe: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Neuroendocrine Tumor Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Neuroendocrine Tumor Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Neuroendocrine Tumor Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Neuroendocrine Tumor Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Neuroendocrine Tumor Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neuroendocrine Tumor Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Neuroendocrine Tumor Drug Market Segments
Table 2. Ranking of Global Top Neuroendocrine Tumor Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Neuroendocrine Tumor Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of mTOR protein inhibitors
Table 5. Major Manufacturers of Tyrosine kinase 3 inhibitors
Table 6. Major Manufacturers of Somatostatin receptor antagonists
Table 7. Major Manufacturers of Growth hormone releasing factor antagonists
Table 8. Major Manufacturers of Somatostatin receptor agonists
Table 9. Major Manufacturers of Others
Table 10. Global Neuroendocrine Tumor Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Neuroendocrine Tumor Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Neuroendocrine Tumor Drug Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Neuroendocrine Tumor Drug Sales Market Share by Regions (2015-2020)
Table 14. Global Neuroendocrine Tumor Drug Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Neuroendocrine Tumor Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Neuroendocrine Tumor Drug Sales Share by Manufacturers (2015-2020)
Table 17. Global Neuroendocrine Tumor Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Neuroendocrine Tumor Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Tumor Drug as of 2019)
Table 19. Neuroendocrine Tumor Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Neuroendocrine Tumor Drug Price (2015-2020) (USD/Pcs)
Table 22. Neuroendocrine Tumor Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Neuroendocrine Tumor Drug Product Type
Table 24. Date of International Manufacturers Enter into Neuroendocrine Tumor Drug Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Neuroendocrine Tumor Drug Sales by Type (2015-2020) (K Pcs)
Table 27. Global Neuroendocrine Tumor Drug Sales Share by Type (2015-2020)
Table 28. Global Neuroendocrine Tumor Drug Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Neuroendocrine Tumor Drug Revenue Share by Type (2015-2020)
Table 30. Neuroendocrine Tumor Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Neuroendocrine Tumor Drug Sales by Application (2015-2020) (K Pcs)
Table 32. Global Neuroendocrine Tumor Drug Sales Share by Application (2015-2020)
Table 33. North America Neuroendocrine Tumor Drug Sales by Country (2015-2020) (K Pcs)
Table 34. North America Neuroendocrine Tumor Drug Sales Market Share by Country (2015-2020)
Table 35. North America Neuroendocrine Tumor Drug Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Neuroendocrine Tumor Drug Revenue Market Share by Country (2015-2020)
Table 37. North America Neuroendocrine Tumor Drug Sales by Type (2015-2020) (K Pcs)
Table 38. North America Neuroendocrine Tumor Drug Sales Market Share by Type (2015-2020)
Table 39. North America Neuroendocrine Tumor Drug Sales by Application (2015-2020) (K Pcs)
Table 40. North America Neuroendocrine Tumor Drug Sales Market Share by Application (2015-2020)
Table 41. Europe Neuroendocrine Tumor Drug Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Neuroendocrine Tumor Drug Sales Market Share by Country (2015-2020)
Table 43. Europe Neuroendocrine Tumor Drug Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Neuroendocrine Tumor Drug Revenue Market Share by Country (2015-2020)
Table 45. Europe Neuroendocrine Tumor Drug Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Neuroendocrine Tumor Drug Sales Market Share by Type (2015-2020)
Table 47. Europe Neuroendocrine Tumor Drug Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Neuroendocrine Tumor Drug Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Neuroendocrine Tumor Drug Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Neuroendocrine Tumor Drug Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Neuroendocrine Tumor Drug Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Neuroendocrine Tumor Drug Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Neuroendocrine Tumor Drug Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Neuroendocrine Tumor Drug Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Neuroendocrine Tumor Drug Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Neuroendocrine Tumor Drug Sales Market Share by Application (2015-2020)
Table 57. Latin America Neuroendocrine Tumor Drug Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Neuroendocrine Tumor Drug Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Neuroendocrine Tumor Drug Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Neuroendocrine Tumor Drug Revenue Market Share by Country (2015-2020)
Table 61. Latin America Neuroendocrine Tumor Drug Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Neuroendocrine Tumor Drug Sales Market Share by Type (2015-2020)
Table 63. Latin America Neuroendocrine Tumor Drug Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Neuroendocrine Tumor Drug Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Neuroendocrine Tumor Drug Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Neuroendocrine Tumor Drug Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Neuroendocrine Tumor Drug Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share by Application (2015-2020)
Table 73. Eisai Corporation Information
Table 74. Eisai Description and Major Businesses
Table 75. Eisai Neuroendocrine Tumor Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. Eisai Product
Table 77. Eisai Recent Development
Table 78. Exelixis, Inc. Corporation Information
Table 79. Exelixis, Inc. Description and Major Businesses
Table 80. Exelixis, Inc. Neuroendocrine Tumor Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Exelixis, Inc. Product
Table 82. Exelixis, Inc. Recent Development
Table 83. Foresee Pharmaceuticals, LLC Corporation Information
Table 84. Foresee Pharmaceuticals, LLC Description and Major Businesses
Table 85. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Foresee Pharmaceuticals, LLC Product
Table 87. Foresee Pharmaceuticals, LLC Recent Development
Table 88. Hutchison MediPharma Limited Corporation Information
Table 89. Hutchison MediPharma Limited Description and Major Businesses
Table 90. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Hutchison MediPharma Limited Product
Table 92. Hutchison MediPharma Limited Recent Development
Table 93. Intezyne, Inc Corporation Information
Table 94. Intezyne, Inc Description and Major Businesses
Table 95. Intezyne, Inc Neuroendocrine Tumor Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Intezyne, Inc Product
Table 97. Intezyne, Inc Recent Development
Table 98. INVENT Pharmaceuticals, Inc. Corporation Information
Table 99. INVENT Pharmaceuticals, Inc. Description and Major Businesses
Table 100. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. INVENT Pharmaceuticals, Inc. Product
Table 102. INVENT Pharmaceuticals, Inc. Recent Development
Table 103. Ipsen S.A. Corporation Information
Table 104. Ipsen S.A. Description and Major Businesses
Table 105. Ipsen S.A. Neuroendocrine Tumor Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Ipsen S.A. Product
Table 107. Ipsen S.A. Recent Development
Table 108. Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
Table 109. Jiangsu Hengrui Medicine Co., Ltd. Description and Major Businesses
Table 110. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Jiangsu Hengrui Medicine Co., Ltd. Product
Table 112. Jiangsu Hengrui Medicine Co., Ltd. Recent Development
Table 113. Karyopharm Therapeutics, Inc. Corporation Information
Table 114. Karyopharm Therapeutics, Inc. Description and Major Businesses
Table 115. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. Karyopharm Therapeutics, Inc. Product
Table 117. Karyopharm Therapeutics, Inc. Recent Development
Table 118. Lexicon Pharmaceuticals, Inc. Corporation Information
Table 119. Lexicon Pharmaceuticals, Inc. Description and Major Businesses
Table 120. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. Lexicon Pharmaceuticals, Inc. Product
Table 122. Lexicon Pharmaceuticals, Inc. Recent Development
Table 123. Midatech Pharma Plc . Corporation Information
Table 124. Midatech Pharma Plc . Description and Major Businesses
Table 125. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 126. Midatech Pharma Plc . Product
Table 127. Midatech Pharma Plc . Recent Development
Table 128. Millennium Pharmaceuticals, Inc. Corporation Information
Table 129. Millennium Pharmaceuticals, Inc. Description and Major Businesses
Table 130. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 131. Millennium Pharmaceuticals, Inc. Product
Table 132. Millennium Pharmaceuticals, Inc. Recent Development
Table 133. MolMed S.p.A. Corporation Information
Table 134. MolMed S.p.A. Description and Major Businesses
Table 135. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 136. MolMed S.p.A. Product
Table 137. MolMed S.p.A. Recent Development
Table 138. Northwest Biotherapeutics, Inc. Corporation Information
Table 139. Northwest Biotherapeutics, Inc. Description and Major Businesses
Table 140. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 141. Northwest Biotherapeutics, Inc. Product
Table 142. Northwest Biotherapeutics, Inc. Recent Development
Table 143. Novartis AG Corporation Information
Table 144. Novartis AG Description and Major Businesses
Table 145. Novartis AG Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 146. Novartis AG Product
Table 147. Novartis AG Recent Development
Table 148. OctreoPharm Sciences GmbH Corporation Information
Table 149. OctreoPharm Sciences GmbH Description and Major Businesses
Table 150. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 151. OctreoPharm Sciences GmbH Product
Table 152. OctreoPharm Sciences GmbH Recent Development
Table 153. OXiGENE, Inc. Corporation Information
Table 154. OXiGENE, Inc. Description and Major Businesses
Table 155. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 156. OXiGENE, Inc. Product
Table 157. OXiGENE, Inc. Recent Development
Table 158. Global Neuroendocrine Tumor Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 159. Global Neuroendocrine Tumor Drug Sales Market Share Forecast by Regions (2021-2026)
Table 160. Global Neuroendocrine Tumor Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 161. Global Neuroendocrine Tumor Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 162. North America: Neuroendocrine Tumor Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 163. North America: Neuroendocrine Tumor Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 164. Europe: Neuroendocrine Tumor Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 165. Europe: Neuroendocrine Tumor Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 166. Asia Pacific: Neuroendocrine Tumor Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 167. Asia Pacific: Neuroendocrine Tumor Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 168. Latin America: Neuroendocrine Tumor Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 169. Latin America: Neuroendocrine Tumor Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 170. Middle East and Africa: Neuroendocrine Tumor Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 171. Middle East and Africa: Neuroendocrine Tumor Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 172. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 173. Key Challenges
Table 174. Market Risks
Table 175. Main Points Interviewed from Key Neuroendocrine Tumor Drug Players
Table 176. Neuroendocrine Tumor Drug Customers List
Table 177. Neuroendocrine Tumor Drug Distributors List
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuroendocrine Tumor Drug Product Picture
Figure 2. Global Neuroendocrine Tumor Drug Sales Market Share by Type in 2020 & 2026
Figure 3. mTOR protein inhibitors Product Picture
Figure 4. Tyrosine kinase 3 inhibitors Product Picture
Figure 5. Somatostatin receptor antagonists Product Picture
Figure 6. Growth hormone releasing factor antagonists Product Picture
Figure 7. Somatostatin receptor agonists Product Picture
Figure 8. Others Product Picture
Figure 9. Global Neuroendocrine Tumor Drug Sales Market Share by Application in 2020 & 2026
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Neuroendocrine Tumor Drug Report Years Considered
Figure 14. Global Neuroendocrine Tumor Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Neuroendocrine Tumor Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Neuroendocrine Tumor Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Neuroendocrine Tumor Drug Sales Market Share by Region in 2019
Figure 19. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Neuroendocrine Tumor Drug Revenue Market Share by Region in 2019
Figure 21. Global Neuroendocrine Tumor Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Neuroendocrine Tumor Drug Revenue in 2019
Figure 23. Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Neuroendocrine Tumor Drug Sales Market Share by Type in 2019
Figure 26. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Neuroendocrine Tumor Drug Revenue Market Share by Type in 2019
Figure 28. Global Neuroendocrine Tumor Drug Market Share by Price Range (2015-2020)
Figure 29. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Neuroendocrine Tumor Drug Sales Market Share by Application in 2019
Figure 31. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Neuroendocrine Tumor Drug Revenue Market Share by Application in 2019
Figure 33. North America Neuroendocrine Tumor Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Neuroendocrine Tumor Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Neuroendocrine Tumor Drug Sales Market Share by Country in 2019
Figure 36. North America Neuroendocrine Tumor Drug Revenue Market Share by Country in 2019
Figure 37. U.S. Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Neuroendocrine Tumor Drug Market Share by Type in 2019
Figure 42. North America Neuroendocrine Tumor Drug Market Share by Application in 2019
Figure 43. Europe Neuroendocrine Tumor Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Neuroendocrine Tumor Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Neuroendocrine Tumor Drug Sales Market Share by Country in 2019
Figure 46. Europe Neuroendocrine Tumor Drug Revenue Market Share by Country in 2019
Figure 47. Germany Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Neuroendocrine Tumor Drug Market Share by Type in 2019
Figure 58. Europe Neuroendocrine Tumor Drug Market Share by Application in 2019
Figure 59. Asia Pacific Neuroendocrine Tumor Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Neuroendocrine Tumor Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Neuroendocrine Tumor Drug Sales Market Share by Region in 2019
Figure 62. Asia Pacific Neuroendocrine Tumor Drug Revenue Market Share by Region in 2019
Figure 63. China Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Neuroendocrine Tumor Drug Market Share by Type in 2019
Figure 86. Asia Pacific Neuroendocrine Tumor Drug Market Share by Application in 2019
Figure 87. Latin America Neuroendocrine Tumor Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Neuroendocrine Tumor Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Neuroendocrine Tumor Drug Sales Market Share by Country in 2019
Figure 90. Latin America Neuroendocrine Tumor Drug Revenue Market Share by Country in 2019
Figure 91. Mexico Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Neuroendocrine Tumor Drug Market Share by Type in 2019
Figure 98. Latin America Neuroendocrine Tumor Drug Market Share by Application in 2019
Figure 99. Middle East and Africa Neuroendocrine Tumor Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Neuroendocrine Tumor Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Neuroendocrine Tumor Drug Revenue Market Share by Country in 2019
Figure 103. Turkey Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Neuroendocrine Tumor Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Neuroendocrine Tumor Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Neuroendocrine Tumor Drug Market Share by Type in 2019
Figure 110. Middle East and Africa Neuroendocrine Tumor Drug Market Share by Application in 2019
Figure 111. North America Neuroendocrine Tumor Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Neuroendocrine Tumor Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Neuroendocrine Tumor Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Asia Pacific Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Neuroendocrine Tumor Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Latin America Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Neuroendocrine Tumor Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Middle East and Africa Neuroendocrine Tumor Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
腫瘍壊死因子阻害薬の世界市場（～2026年） Market Analysis and Insights: Global Tumor Necrosis Factor Inhibitors Drug Market The global Tumor Necrosis Factor Inhibitors Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Tumor Necrosis Factor Inhibitors Drug S…- ソマトスタチン受容体4型の世界市場（～2026年） Market Analysis and Insights: Global Somatostatin Receptor Type 4 Market The global Somatostatin Receptor Type 4 market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Somatostatin Receptor Type 4 Scope and Market Size Somato…
- 腫瘍壊死因子α阻害剤の世界市場（～2026年） The tumor necrosis factor alpha (TNF-a) inhibitors represent one of the major treatment methods for inflammatory diseases. Globally, this drug class is known to be the most successful drugs in the overall pharmaceutical industry. Several conditions such as inflammations, rheumatoid arthritis (RA), i…
- 腫瘍壊死因子阻害剤の世界市場（～2026年） Market Analysis and Insights: Global Tumor Necrosis Factor Inhibitors Market The global Tumor Necrosis Factor Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Tumor Necrosis Factor Inhibitors Scope and Market…
- 神経内分泌がんの世界市場（～2026年） Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the …